Verification and diagnostic evaluation of the RealStar(®) Middle East respiratory syndrome coronavirus (N gene) reverse transcription-PCR kit 1.0

AIM: We report the diagnostic evaluation of a confirmatory reverse transcription-PCR (RT-PCR) kit targeting the Middle East respiratory syndrome coronavirus (MERS-CoV) N gene. MATERIAL & METHODS: 33 patient samples from two collections sites in Riyadh, Saudi Arabia, which were pre-characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Hecht, Leonie-Sophie, Jurado-Jimenez, Angeles, Hess, Markus, Halas, Hussein El, Bochenek, Gregor, Mohammed, Hala, Alzahrani, Fahd, Asiri, Mohammed O, Hasan, Rami, Alamri, Aref, Alotaibi, Sultan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079715/
https://www.ncbi.nlm.nih.gov/pubmed/31271059
http://dx.doi.org/10.2217/fmb-2019-0067
Descripción
Sumario:AIM: We report the diagnostic evaluation of a confirmatory reverse transcription-PCR (RT-PCR) kit targeting the Middle East respiratory syndrome coronavirus (MERS-CoV) N gene. MATERIAL & METHODS: 33 patient samples from two collections sites in Riyadh, Saudi Arabia, which were pre-characterized via real-time RT-PCR targeting MERS-CoV orf1a and upE, and were tested using the MERS-CoV N gene, as a confirmatory assay. This diagnostic procedure follows a two-step diagnostics scheme, recommended by the WHO. RESULTS: 18/33 samples tested positive, 11/33 tested negative for MERS-CoV RNA and 2/33 showed uncertain results. CONCLUSION: The results suggest, that the RealStar(®) MERS-CoV (N gene) RT-PCR kit 1.0 can be considered a suitable and reliable confirmatory assay in combination with the RealStar MERS-CoV RT-PCR kit 1.0 according to the diagnostic scheme recommended by WHO.

Ejemplares similares